Menu
Recruiting NCT05437965

National Multicenter Cohort Registry Study of Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

— Observational Coronary Artery Disease Arteritis In-Stent Stenosis (Restenosis) of Coronary Artery Stent

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Treatment made by experienced clinicians.
Who it may be relevant to
Registry conditions: Coronary Artery Disease, Arteritis, In-Stent Stenosis (Restenosis) of Coronary Artery Stent. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This project aims to establish a clinical cohort and diagnostic assessment framework by conducting a national multicenter cohort registry study. Through the collection of patients' clinical characteristics, it will achieve the registration, management, follow-up, and analysis of patients with Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR).

Interventions

  • Other Treatment made by experienced clinicians
    Treatment made by experienced clinicians

Primary outcome measures

  • Target vessel failure [Time frame: 10 year]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years;
  • Patients meeting the diagnostic criteria for Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR);
  • Patients fully informed about the trial procedures who provide written informed consent.

Exclusion criteria

  • Patients presenting with any of the following:
  • Other severe comorbidities (e.g., malignant tumors, heart failure) with a life expectancy <12 months;
  • Known autoimmune/rheumatic diseases including systemic lupus erythematosus, Takayasu arteritis, Behçet's disease, polyarteritis nodosa, Wegener granulomatosis (granulomatosis with polyangiitis), eosinophilic arteritis, giant cell arteritis, rheumatoid arthritis, or IgG4-related disease;
  • Variant angina (Prinzmetal's angina);
  • Coronary artery dissection;
  • Thrombophilia;
  • Stent underexpansion.
  • Presence of psychiatric disorders;
  • Known inability to complete expected study follow-up for any reason;
  • Patients deemed ineligible for enrollment by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Jia Lei — Beijing

Publications

  • Jia L, Wang K, Lin Z, Yin D, Ren W, Zhang Z, Fang W, Wang L, Dou K. Molecular phenotyping with 18F-FDG and 18F-FAPI PET/CT: advancing risk stratification in in-stent restenosis. Eur J Nucl Med Mol Imaging. 2026 Jul 1. doi: 10.1007/s00259-026-08036-5. Online ahead of print. PMID 42380497

Identifiers

NCT: NCT05437965 · 2021-ZX50

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗